| No. of patients | 257 |
| Dates of transplant | March 1995-January 2000 |
| Mean follow-up (range) (mo) | 12 (1-60) |
| Median age (range) (y) | 42 (16-63) |
| Diagnosis | |
| AML/ALL | 123 (47.8%) |
| CML CP1 | 65 (25.3%) |
| NHL/CLL | 29 (11.3%) |
| MM | 22 (8.6%) |
| MDS | 18 (7%) |
| Phase of disease | |
| Early | 143 (55.6%) |
| Advanced | 114 (44.4%) |
| Sex | |
| F to M | 61 (23.7%) |
| M to M | 80 (31.1%) |
| F to F | 53 (20.6%) |
| M to F | 55 (21.4%) |
| Cytomegalovirus serology | |
| D and R negative | 29 (11.3%) |
| D and/or R positive | 212 (82.5%) |
| D or R NA | 16 (6.2%) |
| ABO incompatibility | |
| Major | 48 (18.7%) |
| Myeloablative regimen | |
| TBI based | 140 (54.5%) |
| Bu based | 117 (45.5%) |
| GVHD prophylaxis | |
| CsA + PDN or MTX | 169 (65.8%) |
| CsA | 82 (31.9%) |
| None | 6 (2.3%) |
| Cell content of the graft* (mean and range) | |
| CD34+ cells | 4 (0.6-15) |
| CD3+ cells | 0.3 (0-2.8) |
| G-CSF posttransplant | 73 (28.4%) |
| Cryopreservation | 72 (28%) |
| No. of patients | 257 |
| Dates of transplant | March 1995-January 2000 |
| Mean follow-up (range) (mo) | 12 (1-60) |
| Median age (range) (y) | 42 (16-63) |
| Diagnosis | |
| AML/ALL | 123 (47.8%) |
| CML CP1 | 65 (25.3%) |
| NHL/CLL | 29 (11.3%) |
| MM | 22 (8.6%) |
| MDS | 18 (7%) |
| Phase of disease | |
| Early | 143 (55.6%) |
| Advanced | 114 (44.4%) |
| Sex | |
| F to M | 61 (23.7%) |
| M to M | 80 (31.1%) |
| F to F | 53 (20.6%) |
| M to F | 55 (21.4%) |
| Cytomegalovirus serology | |
| D and R negative | 29 (11.3%) |
| D and/or R positive | 212 (82.5%) |
| D or R NA | 16 (6.2%) |
| ABO incompatibility | |
| Major | 48 (18.7%) |
| Myeloablative regimen | |
| TBI based | 140 (54.5%) |
| Bu based | 117 (45.5%) |
| GVHD prophylaxis | |
| CsA + PDN or MTX | 169 (65.8%) |
| CsA | 82 (31.9%) |
| None | 6 (2.3%) |
| Cell content of the graft* (mean and range) | |
| CD34+ cells | 4 (0.6-15) |
| CD3+ cells | 0.3 (0-2.8) |
| G-CSF posttransplant | 73 (28.4%) |
| Cryopreservation | 72 (28%) |
AML indicates acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CP, chronic phase; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; MDS, myelodisplastic syndrome; F, female; M, male; D, donor; R, recipient; NA, not available; TBI, total body irradiation; Bu, busulphan; GVHD, graft-versus-host disease; CsA, cyclosporine A; PDN, prednisone; MTX, methotrexate; G-CSF, granulocyte colony-stimulating factor.
×106/kg.